Overview
- GeneDx disclosed on May 4, 2026 that first‑quarter adjusted gross margin fell, full‑year guidance was lowered, and the company took a $31.3 million impairment tied to its April 2025 purchase of Fabric Genomics.
- Plaintiffs’ complaints say GeneDx made false or misleading statements about Fabric’s ability to cut costs and integrate with GeneDx, and they allege executives knew or recklessly disregarded Fabric’s problems.
- Multiple shareholder law firms including Rosen, The Schall Law Firm, and DJS Law Group issued investor notices in mid‑July seeking clients to join the litigation and to move for lead‑plaintiff status.
- Investors who bought GeneDx stock between April 16, 2025 and May 4, 2026 have until August 3, 2026 to move to be lead plaintiff, and no class has been certified so shareholders are not represented by court‑appointed counsel unless they retain one.
- If a lead plaintiff is appointed the case could move into discovery with depositions and document requests that probe what managers knew about Fabric, a common next step in acquisition‑related securities suits that can affect company governance and investor recoveries.